S50 - MS Novel Therapeutics and Animal Models

Event Time: Friday April 28, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Astrocytic Junctional Adhesion Molecule-A (JAM-A) Promotes CNS Inflammatory Lesion Pathogenesis Candice Chapouly, PhD, PharmD
Dr. Horng has nothing to disclose.

1:12 PM 002 CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study David Weinstein
Dr. Weinstein has received personal compensation for activities with InteKrin Therapeutics, Inc. and Coherus BioSciences as a consultant. Dr. Weinstein has received compensation for serving on the Board of Directors and the Scientific Advisory Board of RiverTown Therapeutics, Inc. Dr. Weinstein has received (royalty or license fee or contractual rights) payments from RiverTown Therapeutics Inc.

1:24 PM 003 A high-throughput screen identifies a candidate molecule that promotes remyelination with significant translational potential Kelsey Rankin
Dr. Rankin has nothing to disclose.

1:36 PM 004 Accelerated cellular senescence in a model of multiple sclerosis Dimitrios Papadopoulos, MD
Dr. Papadopoulos has nothing to disclose.

1:48 PM 005 Serum and CSF Neurofilament Light Levels Predict Long-Term Outcomes in Multiple Sclerosis Patients Jens Kuhle
Dr. Kuhle has received research support from Dr Kuhle’s institution (University Hospital Basel) received and used exclusively for research support: consulting fees from Biogen, Novartis, Protagen AG, Roche, Teva; speaker fees from the Swiss MS Society, Biogen, Novartis, Roche, Genzyme; travel expens.

2:00 PM 006 The characterisation of an inducible demyelination zebrafish model to aid the investigation and development of novel therapeutics in multiple sclerosis Alexander McGown, PhD
Dr. McGown has nothing to disclose.

2:12 PM 007 Fc RI (CD64) Receptors Are Widely Expressed on CNS Neurons and Are Required for Neuronal IgG Binding and Uptake: Implications for Antibody-Mediated Neuronal Injury Suzanne Liu
Dr. Liu has nothing to disclose.

2:24 PM 008 Investigating the Role of Fibrinogen and Iron in Inflammatory Demyelination Using Combined High-Resolution MRI and Histopathology in marmoset Experimental Autoimmune Encephalomyelitis Nathanael Lee
Dr. Lee has nothing to disclose.

Register Now

Related Courses